Background
The inadequate sensitivity of available organism-based TB diagnostic tools in children, the wide spectrum of disease observed in children, and the non-specific signs and symptoms especially in young and HIV-children, contribute to diagnostic delay and missed opportunities to detect childhood TB.
Technology
Researchers at Stony Brook have identified changes in a serum lipoprotein that result from a combination of host and TB pathogen activity. The MTB-modified lipoprotein (TLP) is thereby a more specific diagnostic marker for TB disease than the conventional host markers. Development of antibodies against the TLP marker enables the production of a simple in-vitro diagnostic (IVD) assay for pediatric tuberculosis using as finger-prick blood or serum.
Advantages
Non-sputum based diagnostic ELISA test - Novel marker - Novel antibodies to TLP
Application
Diagnostic test for pediatric and adult TB.
Inventors
Nicole Sampson, Professor and Interim Dean, Chemistry
Xinxin Yang, Sr. Postdoctoral Researcher, Chemistry
Licensing Potential
Development partner - Commercial partner - Licensing
Licensing Status
Available for license. Stony Brook is seeking a commercial partner for licensing and/or collaborative research.
Licensing Contact
Valery Matthys, Licensing Associate, Intellectual Property Partners, valery.matthys@stonybrook.edu,
Patent Status
Patent application submitted
Data using serum from pediatric patients. PCT application filed
Tech Id
050-8896